Trial Profile
Placebo-controlled Double-blind Trial of Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Dec 2016
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 19 Dec 2016 Primary endpoint (Overall survival) has not been met, according to results published in the Annals of Oncology journal.
- 19 Dec 2016 Results of this study, published in the Annals of Oncology journal.
- 12 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.